169,530 Shares in Edwards Lifesciences Corporation $EW Acquired by BLI Banque de Luxembourg Investments

BLI Banque de Luxembourg Investments purchased a new position in shares of Edwards Lifesciences Corporation (NYSE:EW) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 169,530 shares of the medical research company’s stock, valued at approximately $14,615,000.

Other hedge funds also recently made changes to their positions in the company. JPL Wealth Management LLC bought a new position in shares of Edwards Lifesciences in the third quarter valued at $25,000. Kohmann Bosshard Financial Services LLC acquired a new stake in Edwards Lifesciences during the 4th quarter valued at $28,000. Hilton Head Capital Partners LLC acquired a new stake in shares of Edwards Lifesciences during the fourth quarter worth $28,000. Hantz Financial Services Inc. lifted its holdings in shares of Edwards Lifesciences by 76.6% during the third quarter. Hantz Financial Services Inc. now owns 378 shares of the medical research company’s stock worth $29,000 after buying an additional 164 shares in the last quarter. Finally, Dorato Capital Management acquired a new stake in shares of Edwards Lifesciences during the fourth quarter worth $29,000. 79.46% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 23,145 shares of the firm’s stock in a transaction dated Wednesday, May 27th. The stock was sold at an average price of $86.42, for a total value of $2,000,190.90. Following the completion of the transaction, the vice president owned 98,611 shares in the company, valued at $8,521,962.62. This trade represents a 19.01% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Daniel J. Lippis sold 1,019 shares of the firm’s stock in a transaction dated Monday, April 6th. The stock was sold at an average price of $80.98, for a total value of $82,518.62. Following the completion of the transaction, the vice president owned 33,934 shares of the company’s stock, valued at approximately $2,747,975.32. This represents a 2.92% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 95,057 shares of company stock worth $7,874,217 in the last quarter. 0.31% of the stock is owned by company insiders.

Edwards Lifesciences Stock Down 0.1%

Shares of NYSE:EW opened at $85.92 on Tuesday. Edwards Lifesciences Corporation has a 1 year low of $72.30 and a 1 year high of $89.48. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.42 and a quick ratio of 3.63. The business has a fifty day moving average price of $82.29 and a two-hundred day moving average price of $83.07. The company has a market capitalization of $49.47 billion, a PE ratio of 45.70, a price-to-earnings-growth ratio of 2.16 and a beta of 0.87.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Thursday, April 23rd. The medical research company reported $0.78 EPS for the quarter, beating analysts’ consensus estimates of $0.73 by $0.05. Edwards Lifesciences had a return on equity of 15.19% and a net margin of 17.39%.The firm had revenue of $1.65 billion for the quarter, compared to analysts’ expectations of $1.60 billion. During the same quarter in the prior year, the firm earned $0.64 EPS. The business’s revenue for the quarter was up 16.7% compared to the same quarter last year. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. Analysts forecast that Edwards Lifesciences Corporation will post 3 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on EW shares. Wolfe Research upgraded Edwards Lifesciences from a “peer perform” rating to an “outperform” rating and set a $92.00 target price on the stock in a research report on Wednesday, April 1st. Robert W. Baird lifted their price objective on Edwards Lifesciences from $85.00 to $87.00 and gave the stock a “neutral” rating in a research note on Friday, April 24th. Evercore reissued an “outperform” rating and issued a $93.00 price target on shares of Edwards Lifesciences in a research note on Friday, April 24th. Canaccord Genuity Group set a $85.00 price target on Edwards Lifesciences and gave the company a “hold” rating in a research note on Friday, April 24th. Finally, Truist Financial set a $90.00 target price on Edwards Lifesciences and gave the stock a “hold” rating in a research report on Friday, April 24th. Three research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and eight have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $95.96.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.